ESR1 and breast cancer: 4OH-tamoxifen (Tam), which is the prototype selective estrogen receptor modulator (SERM), and fulvestrant (Ful, also known as ICI182,780–ICI), which is the prototype selective estrogen receptor down regulator (SERD), act by binding to the ERα and inhibiting receptor activities, which sustain BC cell proliferation [1,2].